Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Purchases $45,600.00 in Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) insider Ingmar Bruns bought 20,000 shares of the company's stock in a transaction that occurred on Thursday, February 6th. The stock was acquired at an average price of $2.28 per share, with a total value of $45,600.00. Following the completion of the purchase, the insider now directly owns 36,629 shares of the company's stock, valued at approximately $83,514.12. The trade was a 120.27 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Zentalis Pharmaceuticals Stock Performance

ZNTL remained flat at $2.43 on Friday. The company had a trading volume of 849,132 shares, compared to its average volume of 3,195,366. The firm has a market cap of $173.16 million, a PE ratio of -0.98 and a beta of 1.81. Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.61 and a 1 year high of $18.07. The firm has a 50-day moving average of $2.65 and a 200 day moving average of $3.11.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ZNTL. Wedbush reissued a "neutral" rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, January 24th. Guggenheim lowered their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a research report on Friday, November 15th. Wells Fargo & Company lowered their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research report on Thursday, January 30th. HC Wainwright decreased their target price on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, January 29th. Finally, UBS Group decreased their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $8.24.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ZNTL. SG Americas Securities LLC boosted its holdings in Zentalis Pharmaceuticals by 84.8% in the third quarter. SG Americas Securities LLC now owns 26,149 shares of the company's stock valued at $96,000 after purchasing an additional 11,997 shares during the last quarter. Exchange Traded Concepts LLC boosted its holdings in Zentalis Pharmaceuticals by 195.3% in the third quarter. Exchange Traded Concepts LLC now owns 45,506 shares of the company's stock valued at $167,000 after purchasing an additional 30,098 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Zentalis Pharmaceuticals by 44.3% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 67,893 shares of the company's stock valued at $250,000 after purchasing an additional 20,848 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Zentalis Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company's stock valued at $50,000 after purchasing an additional 5,333 shares during the last quarter. Finally, Carson Advisory Inc. boosted its holdings in Zentalis Pharmaceuticals by 55.8% in the third quarter. Carson Advisory Inc. now owns 24,570 shares of the company's stock valued at $90,000 after purchasing an additional 8,800 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.